- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04355520
A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
A Phase Ib, Single-arm, Open-label Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Binghe Xu, Doctor
- Phone Number: 010-87788826
- Email: xubinghe@medmail.com.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100021
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Binghe Xu, Doctor
- Phone Number: 010-87788826
- Email: xubinghe@medmail.com.cn
-
Principal Investigator:
- Binghe Xu, Doctor
-
-
Hunan
-
Changsha, Hunan, China, 410600
- Hunan Cancer hospital
-
Contact:
- Quchang Ouyang, Doctor
- Email: oyqc1969@126.com
-
Principal Investigator:
- Quchang Ouyang, Doctor
-
-
Jilin
-
Changchun, Jilin, China, 130021
- The First Hospital of Jilin University
-
Contact:
- Wei Li, Doctor
- Email: jdyylw@163.com
-
Principal Investigator:
- Wei Li, Doctor
-
-
Liaoning
-
Shenyang, Liaoning, China, 110042
- Liaoning cancer hospital
-
Contact:
- Tao Sun, Doctor
- Email: lnzlrxnsy@163.com
-
Principal Investigator:
- Tao Sun, Doctor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Histopathologically confirmed breast cancer. 2. Hormone receptor(HR) positive and human epidermal growth factor receptor-2 (HER2) negative for primary or metastatic tumors confirmed by immunohistochemistry test.
3. Agree to provide at least 10 unstained sections of tumor tissue obtained within 2 years (surgery or biopsy) for genetic mutation detection and with PIK3CA mutation positive.
4. Age ≥18 years, postmenopausal women. 5. Inoperable, locally advanced recurrent and/or metastatic tumor, and has at least one measurable lesion.
6. Inappropriate to receive radical resection or radiation therapy. 7. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
8. Life expectancy ≥12 weeks. 9. Male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study.
10. Understood and signed an informed consent form.
Exclusion Criteria:
1. Has known untreated or active CNS metastasis. 2.Previous or co-existing cancers of a different site or histology from primary breast cancer.
3. Inadequate bone marrow hematopoiesis. 4. Abnormal liver function. 5. Renal abnormalities. 6. Has bleeding risk. 7. Gastrointestinal disorder. 8. Cardio-cerebrovascular anomaly. 9. Previous treatment: A) Has received fulvestrant injection; B) Has received PI3K, AKT and mTOR inhibitors; C) Has received anti-tumor treatment, including chemotherapy, radiotherapy, hormone therapy, biotherapy, immunotherapy, and surgical treatment, less than 4 weeks after the first administration; D) Has received oral targeted drugs less than 5 half-lives to the first administration; E) Has received palliative radiotherapy for non-target lesions within 2 weeks before the first administration; F) Toxicity related to previous anti-tumor treatment did not recover to ≤ grade 1, except for hair loss.
10.Has participated in other clinical trials within 30 days. 11.Has received major surgical treatment within 1 month or unhealed traumatic injury.
12. Has a history of organ transplantation or hematopoietic stem cell transplantation within 60 days prior to the first administration.
13.Immunosuppressant or systemic or absorbable local hormone therapy is required to achieve the aim of immunosuppression (dose > 10mg/ day prednisone or other therapeutic hormones) and is still used within 2 weeks after the first administration.
14.Active bacterial or fungal infections diseases. 15.Human immunodeficiency virus (HIV) infection. 16.Pregnant or lactating female patients. 17.Has mental and neurological diseases. 18. With severe or poorly controlled diseases. 19. Has a history of active tuberculosis. 20. Patients have inadequate compliance to participate in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TQ-B3525 tablets combined with fulvestrant injection
TQ-B3525 tablets were taken orally, once daily in 28-day cycle; fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle.
Each cycle is 28 days.
|
TQ-B3525 tablets were taken orally, once daily in 28-day cycle; The doses were 20 mg and 30 mg.
Fulvestrant injection 500mg administered intravenously (IV) on day 1, day 15 of first cycle and on day 1 of follow-up treatment cycle.
Each cycle is 28 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting toxicity (DLT)
Time Frame: up to 28 days
|
Subjects appear the toxic reaction relate to the drug after treatment within 28 days.
|
up to 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate (ORR) assessed by investigator
Time Frame: up to 72 weeks
|
Percentage of participants achieving complete response (CR) and partial response (PR).
|
up to 72 weeks
|
Disease control rate(DCR)
Time Frame: up to 72 weeks
|
Percentage of participants achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD).
|
up to 72 weeks
|
Duration of Response (DOR)
Time Frame: up to 72 weeks
|
DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.
|
up to 72 weeks
|
Progression-free survival (PFS)
Time Frame: up to 72 weeks
|
PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause.
|
up to 72 weeks
|
Overall survival (OS)
Time Frame: up to 72 weeks
|
OS defined as the time from the first dose to death from any cause.
Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.
|
up to 72 weeks
|
Cmax
Time Frame: Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours post-dose on day 1; Hour 0 of day 15; and hour 0, 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours post-dose on day 28.
|
Cmax is the maximum plasma concentration of TQ-B3525 or metabolite(s).
|
Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours post-dose on day 1; Hour 0 of day 15; and hour 0, 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours post-dose on day 28.
|
Tmax
Time Frame: Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours post-dose on day 1; Hour 0 of day 15; and hour 0, 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours post-dose on day 28.
|
To characterize the pharmacokinetics of TQ-B3525 by assessment of time to reach maximum plasma concentration.
|
Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours post-dose on day 1; Hour 0 of day 15; and hour 0, 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours post-dose on day 28.
|
AUC0-t
Time Frame: Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours post-dose on day 1; Hour 0 of day 15; and hour 0, 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours post-dose on day 28.
|
To characterize the pharmacokinetics of TQ-B3525 by assessment of time to reach maximum plasma concentration.
|
Hour 0, 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours post-dose on day 1; Hour 0 of day 15; and hour 0, 0.5, 1, 2, 3, 4, 6, 8, 11, 24 hours post-dose on day 28.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TQ-B3525-I-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
-
Relay Therapeutics, Inc.Active, not recruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor | Unresectable Solid Tumor | PIK3CA MutationUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHR-positive, HER2-negative Advanced Breast CancerChina
-
Henan Cancer HospitalRecruitingHR Positive HER2 Negative Advanced Breast CancerChina
-
Tianjin Medical University Cancer Institute and...RecruitingHR Positive HER2 Negative Advanced Breast CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHR-positive,HER2-negative in Advanced Breast CancerChina
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
Relay Therapeutics, Inc.RecruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Solid Tumor, Adult | HER2-negative Breast Cancer | Unresectable Solid Tumor | PIK3CA MutationUnited States, Spain, France, Italy
-
Olema Pharmaceuticals, Inc.NovartisRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast CancerUnited States, Australia
-
Biocon Biologics UK LtdNot yet recruitingHR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
-
AstraZenecaCompletedAdvanced Solid Malignancies | Breast Cancer - ER+, HER2 - | Breast Cancer - ER+, HER2-, PIK3CA Gene MutationUnited States, United Kingdom
Clinical Trials on TQ-B3525
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRelapsed or Refractory Lymphoma or Advanced CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownPeripheral T-cell LymphomaChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingDiffuse Large B-cell LymphomaChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownRelapsed / Refractory Mantle Cell Lymphoma (MCL)China
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownRelapsed / Refractory Follicular LymphomaChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingAdvanced Endometrial Cancer, Cervical Cancer and Ovarian CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.TerminatedRelapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingNonsmall-cell Lung CancerChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting